Details of the Drug Reposition

General Information of This Drug (ID: DMF5EK1)

Drug Name
Vilanterol   DMF5EK1
Synonyms
503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pulmonary emphysema DIS5M7HZ CA21.Z Approved [1]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic bronchitis DISS8O8V CA20.1 Discontinued in Phase 2 [2]
Chronic obstructive pulmonary disease DISQCIRF CA22 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Asthma DISW9QNS CA23 Investigative [1]
------------------------------------------------------------------------------------

References

1 Vilanterol FDA Label
2 Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
3 Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome